Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
General & Internal Medicine
Rank in SubField 1: 600 out of 355,674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 13,785 | 15,835 |
| Total Cites | 47,782 | 49,446 |
| H-index | 79 | 83 |
| Hm-index | 30 | 30 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 360 | 370 |
| Number of Single+First Authored Papers | 35 | 35 |
| Total Cites to Single+First Authored Papers | 2,198 | 2,291 |
| Number of Single+First+Last Authored Papers | 97 | 97 |
| Total Cites to Single+First+Last Authored Papers | 10,132 | 10,402 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 40,164 | 41,081 |
| Ratio of Total Citations to Distinct Citing Papers | 1.19 | 1.20 |
| Self-Citation Percentage |
3.37%
|
|
Clark, Gary M.
University of Texas Health Science Center at San Antonio,
United States
2023 Rank: 11,802
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
General & Internal Medicine
Rank in SubField 1: 536 out of 312,644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 11,802 | 13,709 |
| Total Cites | 45,495 | 47,112 |
| H-index | 79 | 82 |
| Hm-index | 29 | 29 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 340 | 349 |
| Number of Single+First Authored Papers | 34 | 34 |
| Total Cites to Single+First Authored Papers | 2,125 | 2,215 |
| Number of Single+First+Last Authored Papers | 98 | 98 |
| Total Cites to Single+First+Last Authored Papers | 9,598 | 9,856 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 37,779 | 38,657 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.22 |
| Self-Citation Percentage |
3.43%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
General & Internal Medicine
Rank in SubField 1: 475 out of 293,195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 10,446 | 12,179 |
| Total Cites | 44,283 | 45,923 |
| H-index | 79 | 82 |
| Hm-index | 29 | 30 |
| Number of Single Authored Papers | 8 | 8 |
| Total Cites to Single Authored Papers | 321 | 330 |
| Number of Single+First Authored Papers | 34 | 34 |
| Total Cites to Single+First Authored Papers | 2,070 | 2,160 |
| Number of Single+First+Last Authored Papers | 100 | 100 |
| Total Cites to Single+First+Last Authored Papers | 9,276 | 9,538 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 36,694 | 37,585 |
| Ratio of Total Citations to Distinct Citing Papers | 1.21 | 1.22 |
| Self-Citation Percentage |
3.57%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
General & Internal Medicine
Rank in SubField 1: 473 out of 271,773 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 10,315 | 11,905 |
| Total Cites | 42,766 | 44,343 |
| H-index | 78 | 81 |
| Hm-index | 28 | 29 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 314 | 323 |
| Number of Single+First Authored Papers | 34 | 34 |
| Total Cites to Single+First Authored Papers | 2,036 | 2,126 |
| Number of Single+First+Last Authored Papers | 96 | 96 |
| Total Cites to Single+First+Last Authored Papers | 8,961 | 9,212 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 35,399 | 36,252 |
| Ratio of Total Citations to Distinct Citing Papers | 1.21 | 1.22 |
| Self-Citation Percentage |
3.56%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.